
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Ligand Pharmaceuticals Incorporated (LGND) is a leading biotechnology business with stocks listed in the US. It opened the day at US$147.3 after a previous close of US$150.21. During the day the price has varied from a low of USD143.16 to a high of USD153.72. The latest price was USD148.22 (25 minute delay). Ligand Pharmaceuticals Incorporated is listed on the NASDAQ. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Open | US$147.3 |
---|---|
High | US$153.72 |
Low | US$143.16 |
Close | US$148.22 |
Previous close | US$150.21 |
Change | US$-1.99 |
Change % | -1.3248% |
Volume | 297,773 |
52-week range | US$57.24 - US$219.75 |
---|---|
50-day moving average | US$150.9527 |
200-day moving average | US$109.5817 |
Target price | US$224.67 |
PE ratio | 4161 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$28.289 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $148.22 on 2021-02-25
1 week (2021-02-19) | 3.74% |
---|---|
1 month (2021-01-26) | -5.51% |
3 months (2020-11-25) | 69.57% |
6 months (2020-08-26) | 40.67% |
1 year (2020-02-26) | 44.44% |
---|---|
2 years (2019-02-26) | 19.70% |
3 years (2018-02-26) | -2.88% |
5 years (2016-02-26) | 52.36% |
Valuing Ligand Pharmaceuticals Incorporated stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ligand Pharmaceuticals Incorporated's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ligand Pharmaceuticals Incorporated's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4161x. In other words, Ligand Pharmaceuticals Incorporated shares trade at around 4161x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Ligand Pharmaceuticals Incorporated's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.6296. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Ligand Pharmaceuticals Incorporated's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Ligand Pharmaceuticals Incorporated's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$50.8 million (£0.0 million).
The EBITDA is a measure of a Ligand Pharmaceuticals Incorporated's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | US$186.4 million |
---|---|
Operating margin TTM | 16.41% |
Gross profit TTM | US$96.6 million |
Return on assets TTM | 1.34% |
Return on equity TTM | -0.4% |
Profit margin | -1.6% |
Book value | 44.133 |
Market capitalisation | US$2.3 billion |
TTM: trailing 12 months
There are currently 6.0 million Ligand Pharmaceuticals Incorporated shares held short by investors – that's known as Ligand Pharmaceuticals Incorporated's "short interest". This figure is 40.4% down from 10.0 million last month.
There are a few different ways that this level of interest in shorting Ligand Pharmaceuticals Incorporated shares can be evaluated.
Ligand Pharmaceuticals Incorporated's "short interest ratio" (SIR) is the quantity of Ligand Pharmaceuticals Incorporated shares currently shorted divided by the average quantity of Ligand Pharmaceuticals Incorporated shares traded daily (recently around 871463.94160584). Ligand Pharmaceuticals Incorporated's SIR currently stands at 6.85. In other words for every 100,000 Ligand Pharmaceuticals Incorporated shares traded daily on the market, roughly 6850 shares are currently held short.
However Ligand Pharmaceuticals Incorporated's short interest can also be evaluated against the total number of Ligand Pharmaceuticals Incorporated shares, or, against the total number of tradable Ligand Pharmaceuticals Incorporated shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ligand Pharmaceuticals Incorporated's short interest could be expressed as 0.37% of the outstanding shares (for every 100,000 Ligand Pharmaceuticals Incorporated shares in existence, roughly 370 shares are currently held short) or 0.6414% of the tradable shares (for every 100,000 tradable Ligand Pharmaceuticals Incorporated shares, roughly 641 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Ligand Pharmaceuticals Incorporated.
Find out more about how you can short Ligand Pharmaceuticals Incorporated stock.
We're not expecting Ligand Pharmaceuticals Incorporated to pay a dividend over the next 12 months.
Ligand Pharmaceuticals Incorporated's shares were split on a 1:6 basis on 19 November 2010. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ligand Pharmaceuticals Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Ligand Pharmaceuticals Incorporated shares which in turn could have impacted Ligand Pharmaceuticals Incorporated's share price.
Over the last 12 months, Ligand Pharmaceuticals Incorporated's shares have ranged in value from as little as US$57.24 up to US$219.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ligand Pharmaceuticals Incorporated's is 1.2716. This would suggest that Ligand Pharmaceuticals Incorporated's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Superhero IPO, plus information on how to buy in.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.
Reddit has long been home to a huge retail investing community called WallStreetBets. Find out how to get the latest Reddit-tipped stocks here.
Steps to owning and managing Koss shares.
Steps to owning and managing Express shares.